Together, the existing research reveals a system of action for SR-17018 that is certainly Plainly distinctive from every other recognized MOP agonist.LSD1 inhibition boosts H3K4 methylation and increases the expression of tumor suppressor genes. This could lead to an inhibition of mobile growth in LSD1-overexpressing tumor cells. In addition, LSD1